Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas
Endocrine · 2024
DOI: 10.1007/s12020-024-03968-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, 2024. Verfasst von Valdemar Máximo und 4 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Lymphatic Metastasis, Thyroid Cancer, Papillary, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Science and Technology, Portugal.
Abstract (Originalsprache)
Purpose
To perform a molecular profiling of the metastases from papillary thyroid carcinomas (PTCs) and poorly differentiated thyroid carcinomas (PDTCs).
Methods
We retrieved and analyzed the molecular and clinical features of 136 metastases from PTCs and 35 metastases from PDTCs subjected to targeted DNA sequencing, from cBioPortal. The clinicopathological data included the number and location of the metastases, and genomic data included mutations, translocations, copy number alterations and fraction of the genome altered (FGA).
Results
Bone metastases from PTCs had a lower frequency of BRAF mutations than the lymph node metastases (LNMs) (43% vs 88%, p < 0.01), and a higher frequency of RBM10 and NRAS mutations than the LNMs (21% vs 3% for both, p < 0.05). The FGA of the bone metastases was higher than the FGA of the lung metastases (5.6% vs 1.3%, p < 0.05). The frequency of RET translocations was higher in the lung metastases from PTCs than the LNMs (15% vs 3%, p < 0.05). The LNMs from PTC patients harboring 4 or more distant metastases (DMs) had a higher frequency of TERT promoter mutations than the LNMs from patients harboring less than 4 DMs (96% vs 65%, p < 0.001). SDHA gene amplifications were enriched in the bone metastases from PDTCs and absent in the LNMs (38% vs 0%, p < 0.05).
Conclusion
Metastases from PTCs and PDTCs harbor clinically relevant alterations affecting distinct body locations, such as NRAS and RBM10 mutations, RET translocations and SDHA amplifications that may be explored therapeutically.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
- IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal.
- Departamento de Patologia e Oncologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
- Departamento de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar e Universitário de Coimbra, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.
- Departamento de Patologia, Hospital São João, Porto, Portugal.
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. arnaud.paula@i3s.up.pt.
Förderung
- Foundation for Science and Technology, Portugal
Zitieren
APA
Máximo, V., Melo, M., Sobrinho-Simões, M., Soares, P., & Da Cruz Paula, A. (2024). Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas. Endocrine. https://doi.org/10.1007/s12020-024-03968-0
Vancouver
Máximo V, Melo M, Sobrinho-Simões M, Soares P, Da Cruz Paula A. Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas. Endocrine. 2024. doi:10.1007/s12020-024-03968-0
BibTeX
@article{Mximo2024,
author = {Máximo, Valdemar and Melo, Miguel and Sobrinho-Simões, Manuel and Soares, Paula and Da Cruz Paula, Arnaud},
title = {Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas},
journal = {Endocrine},
year = {2024},
doi = {10.1007/s12020-024-03968-0}
}
EUVIMED